Wells Fargo analyst Steve Baxter maintained a Hold rating on CVS Health (CVS – Research Report) today and set a price target of $76.00. The company’s shares closed last Friday at $74.58.
According to TipRanks, Baxter is an analyst with an average return of -0.7% and a 44.44% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Humana, Elevance Health, and Molina Healthcare.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CVS Health with a $87.44 average price target.
Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $93.81 billion and a net profit of $2.05 billion. In comparison, last year the company earned a revenue of $83.85 billion and had a net profit of $2.3 billion
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVS Health (CVS) Company Description:
Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.
Read More on CVS:
